Literature DB >> 8554896

Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain.

D E Ott1, L V Coren, D G Johnson, R C Sowder, L O Arthur, L E Henderson.   

Abstract

Previous reports have shown that cyclophilin A (CyPA) is found to be specifically associated with human immunodeficiency virus type-1 (HIV-1) virions and is required for infectivity (Franke et al. Nature 372:359; Thali et al. Nature 372:363). We have examined CyPA associated with HIV-1MN virions. Virions from infected human lymphoid cells were analyzed by high-pressure liquid chromatography (HPLC), protein sequence, and immunoblot analysis. At least three forms of CyPA were found: an unmodified form, an N-terminally modified form, and an N-terminally modified form that migrates as a larger isoform on a reducing-SDS polyacrylamide gel. Using a protease digestion procedure, CyPA that is associated with virions was found to be located inside the viral membrane. Similar examination of SIVMne produced by HUT-78 human T cells did not detect specific incorporation of CyPA into SIV virions. Our results are consistent with the role of CyPA acting early in the infectious process of HIV-1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8554896     DOI: 10.1089/aid.1995.11.1003

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  51 in total

1.  Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy.

Authors:  V M Vogt; M N Simon
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  N-terminal cleavage fragment of glycosylated Gag is incorporated into murine oncornavirus particles.

Authors:  R Fujisawa; F J McAtee; C Favara; S F Hayes; J L Portis
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions.

Authors:  K Gupta; D Ott; T J Hope; R F Siliciano; J D Boeke
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Femtomole SHAPE reveals regulatory structures in the authentic XMRV RNA genome.

Authors:  Jacob K Grohman; Sumith Kottegoda; Robert J Gorelick; Nancy L Allbritton; Kevin M Weeks
Journal:  J Am Chem Soc       Date:  2011-11-29       Impact factor: 15.419

Review 6.  Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection.

Authors:  Jeremy Luban
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

7.  Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1.

Authors:  Cagan Gurer; Lionel Berthoux; Jeremy Luban
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription.

Authors:  James A Thomas; William J Bosche; Teresa L Shatzer; Donald G Johnson; Robert J Gorelick
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Insulin-like growth factor II mRNA binding protein 1 associates with Gag protein of human immunodeficiency virus type 1, and its overexpression affects virus assembly.

Authors:  Yongdong Zhou; Liwei Rong; Jennifer Lu; Qinghua Pan; Chen Liang
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

10.  Three isoforms of cyclophilin A associated with human immunodeficiency virus type 1 were found by proteomics by using two-dimensional gel electrophoresis and matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Shogo Misumi; Takashi Fuchigami; Nobutoki Takamune; Ichiro Takahashi; Michiho Takama; Shozo Shoji
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.